FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Lebwohl David</u>					2. Issuer Name and Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA]							eck all applic Directo	ationship of Reportin k all applicable) Director Officer (give title		son(s) to Issi 10% Ow Other (s	/ner	
	`	ERAPEUTICS,	(Middle) INC.			3. Date of Earliest Transaction (Month/Day/Year) 03/03/2021							below)			below)	
(Street) CAMBR (City)	IDGE M	Ā	02139 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	ndividual or Joint/Group Filing (Check Applicable 2) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - Non	-Deriv	ative	e Se	curities	s Ac	quired, Di	sposed	of, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,		Code (Ins					es ally Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
							Code V	Amour	(A) or (D)	Price	Reported Transact (Instr. 3 a	on(s)			(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security Security Output Derivative Security A. Transaction Date Execution Date, if any (Month/Day/Year)			Date, T		ransaction of Derivative (6. Date Exercisable and Expiration Date (Month/Day/Year)		of Securit Underlyin Derivative	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	ı Title	Amount or Number of Shares					
Stock Option (right to buy)	\$57.71	03/03/2021			A		76,500		(1)	03/02/203	1 Common Stock	76,500	\$0.00	76,50	0	D	
Restricted Stock Unit	(2)	03/03/2021 ⁽²⁾			A		12,750		(2)	(2)	Common Stock	12,750	\$0.00	12,75	0	D	

Explanation of Responses:

1. This option was granted on March 3, 2021 with respect to 76,500 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments

Remarks:

/s/Jose Rivera, Attorney-In-03/05/2021 **Fact**

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} On March 3, 2021, the reporting person was granted 12,750 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments.